Company Profile
Dyno Therapeutics
Company Overview
Dyno Therapeutics is a Cambridge based, VC-backed biotech startup that uses next-gen DNA technologies and machine learning to engineer Adeno-associated Virus (AAV) capsids for the effective delivery of gene therapies.
At Dyno, we are expanding the boundaries of gene therapy. AAV capsids are currently the vector of choice for gene therapy, but they are only a starting point in the gene therapy revolution. Dyno aims to dramatically extend the reach of gene therapy by overcoming the limitations of existing AAV capsids, allowing more therapies to reach the clinic. Doing so will enable treatment for millions of patients with currently incurable, often disabling and deadly diseases.
Dyno’s groundbreaking engineering pipeline harnesses advances in DNA library synthesis, high-throughput sequencing, and machine learning to generate transformative gene therapy vectors. We target the major barriers that separate AAV gene therapy research from real-world therapies, including delivery efficiency, tissue and cell-type specificity, immune evasion, and more. Our vectors will accelerate the transition of gene therapies from the lab to the clinic for the benefit of patients worldwide.